Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy
By Karen Loudon / July 25, 2024
Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line. Cartherics, The University of...
Read More
Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach
By Karen Loudon / June 14, 2024
In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work...
Read More
Cartherics secures Australian patent for innovative cancer cell therapy
By Karen Loudon / June 12, 2024
Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Cartherics granted European patent for multiple development candidates
By Karen Loudon / May 23, 2024
Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer
By Karen Loudon / May 22, 2024
Cartherics’ CEO, Prof. Alan Trounson AO recently presented at Private Capital 2024 held at the ASX Building in Sydney. During...
Read More
Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments
By Karen Loudon / May 14, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics' innovative approach to using stem cells to...
Read More
The first baby from a frozen embryo turns 40!
By Karen Loudon / May 2, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of...
Read More
Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)
By Karen Loudon / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum Background The recent acquisition of ImmunoGen by...
Read More
Cartherics enters into Collaborative Research Agreement with TiCARos
By Karen Loudon / April 2, 2024
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More
Cartherics executes Option Agreement with The Ohio State University
By Karen Loudon / March 20, 2024
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or...
Read More
Cartherics: Leading the Charge in Immunotherapy for Solid Tumours
By Karen Loudon / March 19, 2024
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company's...
Read More
Teal Ribbon Day: Raising awareness for ovarian cancer
By Karen Loudon / February 28, 2024
Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed...
Read More
Cartherics to present and exhibit at Emergence 2024
By Karen Loudon / February 22, 2024
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at...
Read More
Cartherics’ CEO discusses the future of solid tumour therapy
By Karen Loudon / February 15, 2024
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the...
Read More
Ovarian cancer: Biotech company Cartherics to start human trials of new drug
By Karen Loudon / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More
